Highest-materiality recent filing
enGene reports 54% CR at any time in Phase 2 LEGEND trial; 43% CR at 6 months
54% complete response (CR) at any time (67/124) and 43% CR at 6 months (52/121) in BCG-unresponsive NMIBC with CIS.
Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.
enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference
Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
enGene enters $100M at-the-market equity facility with Leerink Partners
New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt
Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.
enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital
Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.
FY2025 net loss $117.3M ($2.29/sh) vs $55.1M ($1.46/sh) in 2024; R&D expenses up $56.2M to $123.2M total OpEx.
enGene prices $130M public offering of common shares and pre-funded warrants
Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.
Detalimogene 62% CR at 6 months; primary endpoint changed; BLA on track H2 2026
Post-protocol amendment patients achieved 62% CR at 6 months (n=37) and 63% at any time (n=62).
enGene Holdings appoints Astley-Sparke and Heffernan to board committees
Philip Astley-Sparke appointed to Audit Committee and Nominating & Corporate Governance Committee.
enGene amends CEO Ron Cooper's severance to 1.5x target bonus on change-in-control termination
Board approved amendment to Cooper Employment Agreement, effective October 2, 2025.
enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead
Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.
enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation
Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.
Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.
enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives
Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.
enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track
Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).
Shareholders approve 2025 Employee Stock Purchase Plan; directors elected
Shareholders approved the 2025 ESPP reserving 2,000,000 common shares for issuance.
enGene signs 5-year lease for 26,335 sq ft Boston office; parent guarantees rent
Lease with 99 High Street Owner LLC for office at 99 High Street, Boston, MA (26,335 rentable square feet).
enGene CMO Dr. Raj Pruthi resigns; effective June 16, 2025
Dr. Raj Pruthi resigned as Chief Medical Officer; resignation date June 3, 2025.
On June 3, 2025, Dr. Raj S. Pruthi notified enGene Holdings Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, with his resignation to be effective as of close of business on June 16, 2025.
Max materiality 0.80 · Median 0.65 · Most common event other_material